Optical density at nm Optical density at nm Optical density Cyclophosphamide at nm Optical density at nm Optical density at nm Optical density at nm mountain cedar polle as confirmed by a positive prick-puncture skin test result to mountain cedar pollen within the past 2 months. Before study ent all patients or their guardians signed an institu-tional review board “approved informed consent agreement . At screeni eligible patients had to have a 2-hour reflective total nasal symptom score of at least of a possible 2 and a congestion score of or ; by randomizati patients had to have a TNSS of at least on separate symptom assessments during the placebo lead-in period. Patients were also required to be in general good health Tofacitinib 540737-29-9 and free of any disease or coitant treatment that could interfere with the interpretation of the study results as determined by the study investigator.
Key exclusion criteria included the following: the pres-ence of any nasal mucosal erosi nasal ulcerati or nasal septal perforation at either screening Silymarin 65666-07-1 or random-ization; other nasal disease likely to affect deposition of intranasal medicati such as sinusit rhinitis medicamen-to clinically significant polypos or nasal structural ab-normalities; nasal surgery or sinus surgery within the previous year; or more than episodes per year of chronic sinusitis. Study Design This randomiz double-bli placebo-controll parallel-group study was conducted at investigational sites during January and February . The study consisted of a -d single-bli placebo lead-in period during which patients were required to have a minimum symptom severity score to be eligible for double-blind treatment.
The placebo lead-in period was fol-lowed by a 4-d double-blind treatment period in which qualified patients were randomized by aputer-generated randomization schedule to treatment with bination azelastine and fluticaso spray per nostril twice dail. azelastine , spray per nostril twice dail. fluticason spray per nostril twice daily in buy Chondroitin diary cards. The 2-hour reflective and instantaneous TNSS assessments were made before the morning and evening doses of study medication. Symptoms were scored on a scale of to , such that the maximum daily symptom severity score was 4. On the first day of the placebo lead-in peri patients were required to have a 2-hour reflective TNSS of at least , to have a nasal congestion score of or , and to me specified study inclusion and exclusion criteria.
Qualified patients then recorded 2-hour reflective and instantaneous TNSS twice daily during the -day placebo lead-in period. To be eligible for double-blind treatme patients were required to have a minimum 2-hour reflective TNSS of for at least symptom assessments during the placebo lead-in period hobby and have a 2-hour reflec-tive nasal congestion score of or for at least symptom assessments . For both TNSS and nasal congesti of the assessments must have occurred within days of day . On days through 4, patients recorded 2-hour reflective and instantaneous TNSS daily in diaries. Patients also recorded the severity of postnasal drip and the 2-hour reflective and instantaneous total ocular symptom scor consisting of itchy ey watery ey and red ey twice daily in diari such that the maximum daily score was 8.